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Objective: S-Nitrosothiols (RSNOs) are bioactive formsof nitric oxidewhich are involved in cell signalling and redox
regulation of vascular function. Circulating S-nitrosothiols are predominantly in the form of S-nitrosoalbumin. In
this study plasma concentrations of S-nitrosothiols were measured in patients with systemic sclerosis (SSc)
where NO metabolism is known to be abnormal.
Patients and methods: Venous blood was collected from 16 patients with Raynaud's phenomenon (RP), 45 with
systemic sclerosis (SSc) (34 patients had limited SSc (IcSSc) and 11 diffuse cutaneous disease (dcSSc)). Twenty
six healthy subjects were used as controls. Plasma S-nitrosothiol concentrations weremeasured by chemilumines-
cence. The measurements were related to the extent of biological age, capillary/skin scores and disease duration.
Results: Plasma RSNO levels in patients with Raynaud's phenomenon (RP) and in those with SSc was signiﬁcantly
lower compared to the concentrations in control subjects. In SSc, plasma S-nitrosothiols were often below the level
of detection (1nM).
Conclusions: Low S-nitrosothiol concentrations were observed in the blood of patients with SSc and patients with
RP indicating a profound disturbance of nitric oxide metabolism.
© 2014 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).1. Introduction
Systemic sclerosis (SSc) is a rheumatic and connective tissue disorder
that affects the skin and the internal organs (lungs, heart, kidney and gut)
leading to tissue ﬁbrosis. The majority of SSc patients exhibit Raynaud's
phenomenon (RP) [1], a vasospastic response to cold which induces
ischemic attacks and vasospasm of the digits [2]. The pathophysiology
of RP includes abnormality of blood vessels, abnormal neural control
mechanisms and platelet activation [3]. Patients with RP do not show
clinical features of SSc. However, some cases may evolve to SSc and ex-
hibit abnormal nail fold capillaries and develop autoantibodies that are
typically observed in patients with SSc [4]. The clinical subgroups of SSc
are classiﬁed into limited SSc (lcSSc) and diffuse cutaneous SSc (dcSSc),
according to their degree and distribution of skin sclerosis, their immu-
nological proﬁle and extent of microvascular dysfunction [5,6].
Several studies have shown that patients with SSc exhibit many fea-
tures suggestive of decreased levels of antioxidant vitamins and enzyme
activities related to defence against oxidative stress [7]. The ﬁbroblasts. This is an open access article undershow increased release of reactive oxygen species [8] and exhibit stress
in their vascular and immune systems and extracellular matrix, which
may contribute to progressive ﬁbrosis [9].
The formation of vasodilator nitric oxide (NO) in normal endothelial
cells [10] has been the focus of study in the pathogenesis of SSc [11–13].
Decreased endothelial NO formation has been reported in SSc patients
[14–16]. However, not all of the evidence points in the same direction
[17]. Inmacrophages, NOproduced by the inducible form of the enzyme
NO synthase (iNOS) is a cytotoxic agent released as part of the primary
defence mechanism against microorganisms. Pulmonary production of
NO is increased as lung macrophages express higher amounts of iNOS
in SSc patients [18]. Elevated levels of nitrite/nitrate have also been
reported in serum of SSc patients [19–21]. The excess NO reacts with
superoxide anions to produce peroxynitrite, an oxidant that nitrates
tyrosine residues in proteins to formnitrotyrosine. The levels of nitrated
proteins in the skin and plasma are increased, especially in patientswith
diffuse SSc at early stages of the disease [13].
S-nitrosothiols (RSNOs) aremore stable formsof bioactiveNO in vivo.
RSNO formation occurs by several pathways including oxidation of thiols
with peroxynitrite [22], or their reaction with N2O3 a product from oxy-
gen and NO [23]. RSNO act as NO donors to speciﬁc thiol-regulatorythe CC BY license (http://creativecommons.org/licenses/by/4.0/).
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nitrosation [24]. RSNOs bind covalently to SH groups of proteins and
lowmolecular weight thiols in vivo and signal through themodiﬁcation
of cysteine (CYS) residues by covalent addition of aNOmoiety, (formally
as NO+), which regulates the function of a broad spectrum of proteins
in cells by S-nitrosylation [25]. The reaction of NO with the free thiols
of serum albumin, cysteine and, to a lesser extent, glutathione results
in the formation of the respective S-nitrosothiols in vivo [26–28].
RSNOs are reduced to NO and nitrite when degraded [29].
We hypothesized that the circulating concentration of RSNOs in SSc
would decrease at an early stage of the disease resulting in endothelial
damage and impaired NO biosynthesis. These changes may contribute
to both the presence of Raynaud's phenomenon and also the ﬁbrotic
changes that ensue in SSc.
2. Materials and methods
2.1. Patients
Patients with RP and systemic sclerosis were enrolled in this study
with the approval of the Royal Free Hospital Ethical Practices subcom-
mittee. RP patients included are those with normal capillaries (NC) and
negative antinuclear–antibody (ANA) and those with NC or ANA or
both, but without evidence of connective tissue disease. Out of 16 RP pa-
tients 6 patients had positive ANA and 4 had abnormal capillaroscopy
and no patient with ANA and with capillaroscopy. The patients with
SSc fulﬁlled the American College of Rheumatology (formerly the
American Rheumatism Association) preliminary diagnostic criteria for
SSc [30] and included patients with lcSSc and dcSSc.
The study was carried out with a total of 61 patients selected ran-
domly and who attended the Rheumatology clinic at the Royal Free
Hospital exhibiting either Raynaud's phenomenon (RP) or SScwith sub-
groups of lcSSc and dcSSc. Bothmale and female patients were included
and none of whom smoked. Twenty six healthy non-smoking subjects
(male and female) were randomly selected and used as controls. In-
formed consent was obtained from all subjects enrolled in the study.
Measurement of RSNO concentrations of patients was carried out blind
and was compared to the skin thickness assessments for SSc patients
measured within three months of the blood samples being taken.
RSNO levels were also related to patient age, capillary/skin scores and
duration of disease.
2.2. Bloods
Venous bloodwas taken frompatients and healthy controls into pre-
chilled tubes containing EDTA (ethylenediaminetetracetic acid ﬁnal
concentration 2 mM) and NEM (N-ethylmaleimide ﬁnal concentration
5 mM) and centrifuged for 10 min at 1300 g at 4 °C. NEM prevented
RSNO degradation by transnitrosation reactions [31] through alkylation
of thiol groups. RSNOswere determined on the day of sample collection.
2.3. Determination of plasma S-nitrosothiols
The assay is based upon the detection of nitric oxide released by
copper, iodine–iodide mediated cleavage of RSNOs to form NO, with
subsequent quantiﬁcation by its gas phase chemiluminescence reaction
with ozone [32]. 8 ml glacial acetic acid and 2 ml KI (50 mg/ml) was
kept in a reaction chamber at 70 °C (custom designed to accommodate
larger sample volume or identical in design to a commercially available
glass chamber (Sievers Radical Purger™)). Oneminute prior to injection
of the sample (200 μl), CuSO4 (200 mM) was added and the solution
purged with N2 and used once per sample. The gas stream was passed
into Sievers InstrumentsModel 280Nitric OxideAnalyser (NOA™ Sievers,
Boulder, Colorado, USA). Data collection and analysis were performed
using theNOAnalysis™ software (Sievers, Boulder, Colorado, USA). To re-
move the background nitrite in plasma samples, sulfanilamide 0.5% (w/v)in HCl (ﬁnal concentration 0.2 M) was added. This forms a stable diazo-
nium salt and prevents NO formation. Antifoam™ (Sievers, Boulder,
Colorado, USA) in 1:30 dilution in deionised water was added to the
plasma at a ratio of 1:9, immediately before injection of the sample.
100–1000 μl plasma extracts were injected to the reaction chamber,
before and after addition of CuSO4 in order to calculate the level of
S-nitrosothiol and exclude N-nitrosamine or iron nitrosyl. The NO2−
measurements were taken by chemiluminescence before the addition
of CuSO4, whereas concentrations of S-nitrosothiols were determined
after the addition of CuSO4 to the reaction chamber with sulfanilamide.
RSNO concentrations were calculated by subtraction of the value of
NO2− from the value received after injection in CuSO4.
2.4. Preparation of standard (SNOalb)
Standard curves for SNO-albumin (SNO-alb) were obtained over the
range of 1nM to 5 μM by addition of known amounts of SNO-alb to
PBS with 5 mM NEM. To prepare SNO-albumin human serum albumin
(20 mg/ml) was treated with dithiothreitol in phosphate buffer saline
(PBS) together with 100 μM diethyleneaminepenta-acetic acid (DTPA)
and gently stirred at 20 °C for 2 h to reduce the Cys-34 thiol group.
The sample was dialysed extensively in Visking tubing ((Medicell,
London, UK) molecular weight cut off 14,000) at 4 °C against 3 × 3 L.
PBS, pH 7.4 containing 100 μMDTPA. Any untreated thiol was alkylated
with NEM (1mM) at room temperature and dialysed against PBS/DTPA.
The stock solution of SNO-alb was stored at−20 °C. SNO-alb wasmea-
sured prior to use by the Saville reaction [33].
2.5. Skin scores
Tightness and thickening of skin were measured in the majority of
SSc patient using the modiﬁed Rodnan skin score method [34]. The
total skin surface area was divided into 17 different areas: the skin
score evaluated in each by manual palpation. The skin score grading
was0 for uninvolved skin, 1 formild thickening, 2 formoderate thicken-
ing, and 3 for severe thickening (hidebound skin). The total skin score
was the sum of the skin scores of the individual areas, the maximum
possible score being 51. The skin scores correlate with the extent of der-
malﬁbrosis and the extent ofﬁbrosis and dysfunction of internal organs.
2.6. Nailfold Capillary scores (NC) were measured as described in Ref. [35]
2.6.1. Data analysis
Data were expressed as mean ± SE where n was the number of
individual samples assayed in duplicate or more. Comparisons of multi-
ple means were performed using a one way ANOVA followed by the
Student's Newman–Keuls test. Correlation and regression were per-
formed using the ‘least squares’ method in the Microsoft Excel pro-
gramme. P value of b0.05 was considered as statistically signiﬁcant.
3. Results
3.1. Demographic data of patients and controls
The characteristics of controls and patients are described in Table 1.
The age range was similar in each group but the controls had a higher
proportion of males.
3.2. Plasma RSNOs in healthy controls: effects of age
The concentrations of RSNOs in healthy controls were relatively low
compared to those reported using other methods, and rather below
those measured for controls by the originators of this procedure [32].
However the mean age of this cohort is likely to have been higher and
reﬂects a population with a wide age range which seems to inﬂuence
Table 1
Demographic data for patients and controls:
Mean age, age range andmales/females ratiowere reported for healthy controls (HC) and
in patients with Raynaud's phenomenon (RP), systemic sclerosis (SSc), limited SSc (lcSSc)
and diffuse cutaneous SSc (dcSSc).
Subjects Number studied
(Individuals)
Age range
(Years)
Mean age
(mean ± SEM)
Males/
females
Healthy Controls 26 22–60 41 ± 2 10/16
Patients:
RP 16 15–78 46 ± 1 2/14
SSc 45 40–97 58 ± 2 8/37
lcSSc 34 40–97 63 ± 3 6/28
dcSSc 11 41–61 47 ± 2 2/9
(B). Number of individuals (males/females) available for skin score data
Patients: Number studied
(Individuals)
Skin score
range
Mean skin score
(mean ± SEM)
Males/
females
SSc (skin score) 36 0–47 17 ± 2 6/30
lcSSc (skin score) 25 0–23 10 ± 1 4/21
dcSSc (skin score) 11 12–47 31 ± 3 3/8
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P= 2.67 × 10−6, n = 26) but the relationship was not linear.
At ages below 36 in the controls RSNO levels appeared to be higher
(6.36 ± 1.1 nM; n = 11) and correlated negatively to age (r2 = 0.34;
P = 0.015); whereas as age increased to 60, RSNO values were lower
at 4.03 ± 1 nM; n = 15 and within this subgroup were not correlated
with age (r2 = 0.04; P= 0.12).3.3. Plasma RSNOs in RP and SSc patients
Plasma RSNO levels in healthy controls (6.0± 0.8 nM; n=26)were
signiﬁcantly higher than those of all patients taken together (RP and
SSc) (1.38 ± 0.4 nM; n = 61, P= 2.58 × 10−8). RP patients alone had
lower levels than those of controls (2.12 ± 0.6 nM; n = 16; P =
0.002). Even lower levels were found in SSc patients (1.17 ± 0.5 nM;
n = 45, P= 2. 58 × 10−8). Within the SSc subgroups, the RSNO levels
were again signiﬁcantly lower than controls (IcSSc 1.31 ± 0.37 nM;
n = 34, P = 1.06 × 10−6; dcSSc, 0.73 ± 0.41; n = 11; P = 0.00254)
but not between each other (P= 0.34) (Fig. 1). There was no correla-
tion between plasma RSNO and age or gender within any of the patient
groups [not shown].P=2.58x10-8
P=0.002
P=1.06x10-6
P=0.0025
Fig. 1. Individual levels of S-nitrosothiol (RSNO) in plasma of healthy controls, Raynaud's
phenomenon (RP), SSc systemic sclerosis (SSc), lcSSc (limited SSc) and dcSSc (diffuse
cutaneous disease) patients. RSNO levels were detected by a NO chemiluminescence
detector (NOA 280, Sievers). Horizontal bars represent median values observed in each
group. Results obtain in each group were compared to the results obtained in healthy
controls (one way ANOVA followed by the students Newman–Keuls test). P b 0.05 was
considered statistically signiﬁcant.3.4. Correlation of RSNO levels with capillary/skin scores and
disease duration
RSNO values of the RP group correlated negatively to the capillary
scores (r2 = 0.18, P = 0.03). The skin scores for all SSc patients were
on average 16.5 ± 2.02 (n = 36), in the lcSSc group alone 10.1 ± 1
(n = 25) and in dcSSc patients 30.9 ± 3.1 (n = 11) respectively. The
RSNO levels correlated negatively to the skin scores (r2 = 0.20, P =
0.002, n = 25) in lcSSc. In the total SSc cohort, the correlation was
also signiﬁcant (r2= 0.08, P= 0.001, n=36) but a large number of pa-
tients had undetectable RSNOs making a generalizable relationship dif-
ﬁcult to sustain. RSNOs were negatively correlated to the duration (in
years) of the disease in the SSc patients (r2 = 0.26; P= 0.001 n= 36).4. Discussion
In this study S-nitrosothiol levels in plasmaof patientswith systemic
sclerosis and those with Raynaud's phenomenon were reported. As in
most previous studies, the patient cohort had an excess of females to
males. The onset of disease is more common after the ﬁfth decade of
life, although it is also found in younger patients [36]. The prevalence
of lSSc and diffuse subsets were in a similar proportion to those found
in other studies [37]. RSNO levels in both controls and patients were
low but consistent with those where chemiluminescence detection
[32] was employed. Elevated levels of S-nitrosoalbumin and total
S-nitrosothiol concentrations in pre-eclampsia plasma were reported
using this technique [38]. A variety of techniques have been used to
measure RSNO [39,40] but there is no consensus about which is the
best. However, earlier estimates placing the levels of these compounds
in themicromolar range are unlikely to be accurate, because of the pro-
found effects they would have on blood pressure [41].
In these studies we found that RSNO levels were higher in the
healthy controls compared to those over the age of thirty six, especially
if theywere young. Theﬁnding is consistentwith earlier reports that NO
biosynthesis in endothelial cells was reduced with age [42,43] an effect
associated with increasing apoptosis [44]. Age may contribute to the
low levels of RSNO in patients with SSc and RP, but this appears not to
be the only factor, since many patients have RSNOs below the mea-
sureable threshold. These very low values were not found in any of
the controls. The low levels of RSNOs are consistent with previous stud-
ies showing severe disturbances in nitric oxide metabolism in these
diseases e.g. increased nitrated proteins and ADMA [13] especially in
diffuse SSc.
The reduction of RSNOs in patients with IRP is less consistent, but
accords with reports that show disturbances in NO metabolism in
these patients [13]. In contrast, in SSc, NO releasemay be increased tran-
sitorily because of the induction of NOSII [12].
The reduction in the level of RSNOs in SSc may track a gradual dete-
rioration of endothelial function post the inﬂammatory phase of the
disease, but low levels were also found in several of the RP patients
suggesting that the fall may occur at an early stage in some cases. The
decline of RSNOs was also parallel to increasing skin score, which high-
lights earlier observations where nitric oxide inhibits collagen secretion
in human dermal ﬁbroblasts through a cGMP-independent regulatory
mechanism by activation of matrix metalloproteinase-1 [45]. The inhi-
bition was less effective in SSc ﬁbroblasts. However these correlations
should be regarded with caution as there were many patients who
had undetectable levels of RSNO.
The low plasma levels of ascorbic acid in SScmay also contribute to a
reduction in NO biosynthesis or by reducing thiol availability [46]. Re-
cent work suggests that S-nitrosothiols and products of S-nitrosylation
play key roles in human health and disease.
An understanding of the factors that determine RSNO levels in vivo
and the reasons why aberrant depletion of intracellular RSNOs contrib-
utes to disease are beginning to emerge [47].
181D. Kundu et al. / Vascular Pharmacology 63 (2014) 178–1815. Conclusion
The ﬁndings in this study strengthen the view that NOmetabolism is
profoundly disturbed in SSc and that low levels of RSNOmay play a key
role in its progress. This may inﬂuence not only the universal existence
of RP in SSc patients, but also abnormalities in platelet activation, the
regulation of collagen activity and defective angiogenesis. The evalua-
tion and study of the concentration of RSNOs in plasma of patients in
RP and SSc and correlation with some clinical markers may help to im-
prove safe treatment with NO donor drugs.
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